2003, Clinical Development, FDA Approval and Treatment

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2003

Clinical Development

FDA Approval

Treatment

Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

The Pharma Data

APRIL 14, 2021

Xolair for self-injection offers healthcare providers and appr opriate patients another administration option for more flexibility in managing their treatment. Roche’s Chief Medical Officer and Head of Global Product Development. with Xolair since its initial approval in 2003. today announced that the U.S. indications.

FDA Approval

FDA Approval Clinical Development FDA Licensing

Analysis Life Sciences Thank You FDA’s nonprescription advisors find no efficacy for phenylephrine

Agency IQ

SEPTEMBER 15, 2023

Until recently, the FDA relied on a monograph process through which firms could bring OTC drugs to market without FDA approval so long as it adhered to pre-set terms under the monograph. The FDA will follow these procedures for both agency-initiated operations (e.g., He penned thoughts on LinkedIn following the vote.

Science

Science FDA Clinical Trials Pharmacy

Drug Discovery Digest

Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

Analysis Life Sciences Thank You FDA’s nonprescription advisors find no efficacy for phenylephrine

Stay Connected